



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Chi Chiu Wang
✉ ccwang@cuhk.edu.hk

RECEIVED 07 November 2025
ACCEPTED 12 November 2025
PUBLISHED 24 November 2025

CITATION
He Y, Hung SW, Liang B, Zhang R, Gao Y,
Chu CY, Zhang T, Xu H, Chung JPW and
Wang CC (2025) Correction: Receptor
tyrosine kinase inhibitor sunitinib as novel
immunotherapy to inhibit myeloid-derived
suppressor cells for treatment of
endometriosis.
Front. Immunol. 16:1741271.
doi: 10.3389/fimmu.2025.1741271

COPYRIGHT
© 2025 He, Hung, Liang, Zhang, Gao, Chu,
Zhang, Xu, Chung and Wang. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis

Ying He¹, Sze Wan Hung¹, Bo Liang¹, Ruizhe Zhang¹,
Yating Gao¹, Ching Yan Chu¹, Tao Zhang¹, Hui Xu¹,
Jacqueline Pui Wah Chung¹ and Chi Chiu Wang^{1,2,3,4*}

¹Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China, ²Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China, ³School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China, ⁴Chinese University of Hong Kong–Sichuan University Joint Laboratory in Reproductive Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China

KEYWORDS

endometriosis, myeloid-derived suppressor cells, Sunitinib, immunosuppression, gene expressions

A Correction on

Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis

By He Y, Hung SW, Liang B, Zhang R, Gao Y, Chu CY, Zhang T, Xu H, Chung JPW and Wang CC (2021). *Front. Immunol.* 12:641206. doi: 10.3389/fimmu.2021.641206

An incorrect **Funding** statement was provided. The correct **Funding** statement reads: “This research was supported by The Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from Hong Kong Society of Obstetricians and Gynaecologists; Academic Equipment Grant (3029876); and Direct Grant (2017.044) from The Chinese University of Hong Kong.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.